Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer

Johannes F. Fahrmann, Kyoungmi Kim, Brian C. DeFelice, Sandra L. Taylor, David R Gandara, Ken Y Yoneda, David T Cooke, Oliver Fiehn, Karen Kelly, Suzanne Miyamoto

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: Untargeted metabolomics was used in case-control studies of adenocarcinoma (ADC) lung cancer to develop and test metabolite classifiers in serum and plasma as potential biomarkers for diagnosing lung cancer. Methods: Serum and plasma were collected and used in two independent case-control studies (ADC1 and ADC2). Controls were frequency matched for gender, age, and smoking history. There were 52 adenocarcinoma cases and 31 controls in ADC1 and 43 adenocarcinoma cases and 43 controls in ADC2. Metabolomics was conducted using gas chromatography time-of-flight mass spectrometry. Differential analysis was performed on ADC1 and the top candidates (FDR <0.05) for serum and plasmausedto develop individual and multiplex classifiers that were then tested on an independent set of serum and plasma samples (ADC2). Results: Aspartate provided the best accuracy (81.4%) for an individual metabolite classifier in serum, whereas pyrophosphate had the best accuracy (77.9%) in plasma when independently tested. Multiplex classifiers of either 2 or 4 serum metabolites had an accuracy of 72.7% when independently tested. For plasma, a multimetabolite classifier consisting of 8 metabolites gave an accuracy of 77.3% when independently tested. Comparison of overall diagnostic performance between the two blood matrices yielded similar performances. However, serum is most ideal given higher sensitivity for low-abundant metabolites. Conclusion: This study shows the potential of metabolite-based diagnostic tests for detection of lung adenocarcinoma. Further validation in a larger pool of samples is warranted. Impact: These biomarkers could improve early detection and diagnosis of lung cancer. Cancer Epidemiol Biomarkers

Original languageEnglish (US)
Pages (from-to)1716-1723
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume24
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Metabolomics
Lung Neoplasms
Biomarkers
Serum
Case-Control Studies
Adenocarcinoma
Tumor Biomarkers
Adenocarcinoma of lung
Routine Diagnostic Tests
Aspartic Acid
Gas Chromatography
Early Diagnosis
Mass Spectrometry
Smoking
History

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. / Fahrmann, Johannes F.; Kim, Kyoungmi; DeFelice, Brian C.; Taylor, Sandra L.; Gandara, David R; Yoneda, Ken Y; Cooke, David T; Fiehn, Oliver; Kelly, Karen; Miyamoto, Suzanne.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 24, No. 11, 01.11.2015, p. 1716-1723.

Research output: Contribution to journalArticle

Fahrmann, Johannes F. ; Kim, Kyoungmi ; DeFelice, Brian C. ; Taylor, Sandra L. ; Gandara, David R ; Yoneda, Ken Y ; Cooke, David T ; Fiehn, Oliver ; Kelly, Karen ; Miyamoto, Suzanne. / Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer. In: Cancer Epidemiology Biomarkers and Prevention. 2015 ; Vol. 24, No. 11. pp. 1716-1723.
@article{bccb10e0895d47ac8c8aaa41b669472f,
title = "Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer",
abstract = "Background: Untargeted metabolomics was used in case-control studies of adenocarcinoma (ADC) lung cancer to develop and test metabolite classifiers in serum and plasma as potential biomarkers for diagnosing lung cancer. Methods: Serum and plasma were collected and used in two independent case-control studies (ADC1 and ADC2). Controls were frequency matched for gender, age, and smoking history. There were 52 adenocarcinoma cases and 31 controls in ADC1 and 43 adenocarcinoma cases and 43 controls in ADC2. Metabolomics was conducted using gas chromatography time-of-flight mass spectrometry. Differential analysis was performed on ADC1 and the top candidates (FDR <0.05) for serum and plasmausedto develop individual and multiplex classifiers that were then tested on an independent set of serum and plasma samples (ADC2). Results: Aspartate provided the best accuracy (81.4{\%}) for an individual metabolite classifier in serum, whereas pyrophosphate had the best accuracy (77.9{\%}) in plasma when independently tested. Multiplex classifiers of either 2 or 4 serum metabolites had an accuracy of 72.7{\%} when independently tested. For plasma, a multimetabolite classifier consisting of 8 metabolites gave an accuracy of 77.3{\%} when independently tested. Comparison of overall diagnostic performance between the two blood matrices yielded similar performances. However, serum is most ideal given higher sensitivity for low-abundant metabolites. Conclusion: This study shows the potential of metabolite-based diagnostic tests for detection of lung adenocarcinoma. Further validation in a larger pool of samples is warranted. Impact: These biomarkers could improve early detection and diagnosis of lung cancer. Cancer Epidemiol Biomarkers",
author = "Fahrmann, {Johannes F.} and Kyoungmi Kim and DeFelice, {Brian C.} and Taylor, {Sandra L.} and Gandara, {David R} and Yoneda, {Ken Y} and Cooke, {David T} and Oliver Fiehn and Karen Kelly and Suzanne Miyamoto",
year = "2015",
month = "11",
day = "1",
doi = "10.1158/1055-9965.EPI-15-0427",
language = "English (US)",
volume = "24",
pages = "1716--1723",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Investigation of metabolomic blood biomarkers for detection of adenocarcinoma lung cancer

AU - Fahrmann, Johannes F.

AU - Kim, Kyoungmi

AU - DeFelice, Brian C.

AU - Taylor, Sandra L.

AU - Gandara, David R

AU - Yoneda, Ken Y

AU - Cooke, David T

AU - Fiehn, Oliver

AU - Kelly, Karen

AU - Miyamoto, Suzanne

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Background: Untargeted metabolomics was used in case-control studies of adenocarcinoma (ADC) lung cancer to develop and test metabolite classifiers in serum and plasma as potential biomarkers for diagnosing lung cancer. Methods: Serum and plasma were collected and used in two independent case-control studies (ADC1 and ADC2). Controls were frequency matched for gender, age, and smoking history. There were 52 adenocarcinoma cases and 31 controls in ADC1 and 43 adenocarcinoma cases and 43 controls in ADC2. Metabolomics was conducted using gas chromatography time-of-flight mass spectrometry. Differential analysis was performed on ADC1 and the top candidates (FDR <0.05) for serum and plasmausedto develop individual and multiplex classifiers that were then tested on an independent set of serum and plasma samples (ADC2). Results: Aspartate provided the best accuracy (81.4%) for an individual metabolite classifier in serum, whereas pyrophosphate had the best accuracy (77.9%) in plasma when independently tested. Multiplex classifiers of either 2 or 4 serum metabolites had an accuracy of 72.7% when independently tested. For plasma, a multimetabolite classifier consisting of 8 metabolites gave an accuracy of 77.3% when independently tested. Comparison of overall diagnostic performance between the two blood matrices yielded similar performances. However, serum is most ideal given higher sensitivity for low-abundant metabolites. Conclusion: This study shows the potential of metabolite-based diagnostic tests for detection of lung adenocarcinoma. Further validation in a larger pool of samples is warranted. Impact: These biomarkers could improve early detection and diagnosis of lung cancer. Cancer Epidemiol Biomarkers

AB - Background: Untargeted metabolomics was used in case-control studies of adenocarcinoma (ADC) lung cancer to develop and test metabolite classifiers in serum and plasma as potential biomarkers for diagnosing lung cancer. Methods: Serum and plasma were collected and used in two independent case-control studies (ADC1 and ADC2). Controls were frequency matched for gender, age, and smoking history. There were 52 adenocarcinoma cases and 31 controls in ADC1 and 43 adenocarcinoma cases and 43 controls in ADC2. Metabolomics was conducted using gas chromatography time-of-flight mass spectrometry. Differential analysis was performed on ADC1 and the top candidates (FDR <0.05) for serum and plasmausedto develop individual and multiplex classifiers that were then tested on an independent set of serum and plasma samples (ADC2). Results: Aspartate provided the best accuracy (81.4%) for an individual metabolite classifier in serum, whereas pyrophosphate had the best accuracy (77.9%) in plasma when independently tested. Multiplex classifiers of either 2 or 4 serum metabolites had an accuracy of 72.7% when independently tested. For plasma, a multimetabolite classifier consisting of 8 metabolites gave an accuracy of 77.3% when independently tested. Comparison of overall diagnostic performance between the two blood matrices yielded similar performances. However, serum is most ideal given higher sensitivity for low-abundant metabolites. Conclusion: This study shows the potential of metabolite-based diagnostic tests for detection of lung adenocarcinoma. Further validation in a larger pool of samples is warranted. Impact: These biomarkers could improve early detection and diagnosis of lung cancer. Cancer Epidemiol Biomarkers

UR - http://www.scopus.com/inward/record.url?scp=84946559080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946559080&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-15-0427

DO - 10.1158/1055-9965.EPI-15-0427

M3 - Article

C2 - 26282632

AN - SCOPUS:84946559080

VL - 24

SP - 1716

EP - 1723

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 11

ER -